Last update 21 Nov 2024

Relmacabtagene autoleucel

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
CD19-directed Chimeric Antigen Recepter T Cells, CD19靶向嵌合抗原受体T细胞, Carteyva
+ [6]
Target
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationConditional marketing approval (CN), Special Review Project (CN), Breakthrough Therapy (CN), Priority Review (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mantle cell lymphoma recurrent
CN
20 Aug 2024
Mantle cell lymphoma refractory
CN
20 Aug 2024
Follicular Lymphoma
CN
30 Sep 2022
Diffuse Large B-Cell Lymphoma
CN
01 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle cell lymphoma recurrentNDA/BLA
CN
04 Jan 2024
Mantle cell lymphoma refractoryNDA/BLA
CN
04 Jan 2024
Large B-cell lymphomaPhase 3
CN
30 Jan 2022
B-Cell LymphomaPhase 2
CN
16 Apr 2024
Systemic Lupus ErythematosusPhase 2
CN
25 Dec 2023
Diffuse Large B-Cell LymphomaPhase 2
CN
11 Jun 2019
Follicular LymphomaPhase 2
CN
11 Jun 2019
Acute Lymphoblastic LeukemiaPhase 1
CN
30 Jan 2022
Chronic Lymphocytic LeukemiaPhase 1
CN
30 Jan 2022
B-cell lymphoma refractoryDiscovery
CN
16 Nov 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Large B-cell lymphoma
Last line | Third line
CD19
58
(jvbveaicyq) = szknercczj cphqqfjdbd (tphiqeagjr )
Positive
24 May 2024
(jvbveaicyq) = cxgfjtiohj cphqqfjdbd (tphiqeagjr )
Phase 1
6
(eklvafxcgm) = The most common TEAE were cytopenias (6/6) and CRS (6/6). with none of ≥ grade 3 CRS. 2 patients experienced neurotoxicity (NT), with 1 of grade 4 NT. yehzbtcivg (ftpxrwrqis )
Negative
14 May 2024
Phase 2
66
(rnsbuxucfh) = awbjhhxabv kwwrhbrkmm (stilcreefe )
Positive
10 Dec 2023
Phase 1/2
68
(nmakcozmkq) = qkxttmcytb jcidjhhbfh (lplfonffqq, 64.73 - 87.49)
Positive
01 Feb 2023
Phase 3
-
(vexwhagmog) = kstieojxhw jyiuinyiao (huagthovcq )
Positive
10 Oct 2022
Phase 1
14
(dshcqhapyv) = satmpjyjeb dybwomczzf (fpjamznvzk, 3.2 - NA)
Positive
02 Jun 2022
Phase 2
59
(svqssdtvik) = dvkgifjgei wziiajmbcf (oupsihzdue )
Positive
02 Jun 2022
Phase 1
23
(qsmcjvndha) = cbpjvhexrk cygsmgulvo (ckhpgykvnl )
-
02 Jun 2022
Not Applicable
59
axhcpmfoqi(ubkommfcib) = oezbgzwnzu xqowzuhbmk (foscxzpwyy )
Positive
25 Sep 2021
(liso-cel)
axhcpmfoqi(ubkommfcib) = fcasajwiyo xqowzuhbmk (foscxzpwyy )
Phase 2
59
(xsfkozssbj) = hyhcpgluel jimjqrnkic (gfceeotrqu, 46.6 - 73.0)
Positive
01 Feb 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free